Response monitoring of breast cancer patientsreceiving neoadjuvant chemotherapy using breast MRI – a review of current knowledge

Lobbes, Marc; Prevos, Renate; Smidt, Marjolein L.

doi:10.7243/2049-7962-1-34

Cited by 25 publications

(26 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recent studies have also looked at parameters that could assess the response to chemotherapy, by using highly specific radiologic techniques such as MRI and MR spectroscopy [17,18]. However, the assessment of residual tumour disease by using these techniques could be influenced by factors such as subtype of breast cancer, chemotherapy regimen, marker artifact, which could lead to over or underestimation of the residual disease.…”

Section: Clinical Response Categoriesmentioning

confidence: 99%

Study of Tumour Cellularity in Locally Advanced Breast Carcinoma on Neo-Adjuvant Chemotherapy

Kumar

Badhe

Krishnan

et al. 2014

JCDR

View full text Add to dashboard Cite

Section: Clinical Response Categoriesmentioning

confidence: 99%

Study of Tumour Cellularity in Locally Advanced Breast Carcinoma on Neo-Adjuvant Chemotherapy

Kumar

Badhe

Krishnan

et al. 2014

JCDR

View full text Add to dashboard Cite

“…Of these parameters, (ADC) values of DWI are the most important with the greatest advantage observed with the use of volumetric measurement of tumor response early in treatment (Hylton et al, 2012;Lobbes et al, 2012;ACR, 2013). chemotherapy has been completed to monitor if there are signs of early response to the primary treatment.…”

Section: Monitoring Response To Neoadjuvant Chemotherapymentioning

confidence: 99%

“…Even if residual disease is not evident by MRI, surgical resection is advised due to the potential underestimation of residual disease (Hylton et al, 2012;Lobbes et al, 2012;Tejerina et al, 2012).…”

Section: Monitoring Response To Neoadjuvant Chemotherapymentioning

confidence: 99%

Breast Magnetic Resonance Imaging Indications in Current Practice

Abdulkareem¹

2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Asian Pac J Cancer Prev, 15 (2), 569-575 IntroductionIn the last few years, magnetic resonance imaging (MRI) has emerged as an adjunctive tool to mammography in the assessment of various breast conditions. The high sensitivity for cancer detection allows it to be used in evaluating several aspects of breast cancer diagnosis and treatment. The American Cancer Society (ACS) and the American College of Radiology (ACR) have discussed this issue and suggested several scenarios in which breast MRI can be used for both diagnostic and screening purposes (Saslow et al., 2007;Argus and Mahoney, 2010;ACR, 2013). However; controversy is still present regarding which of these indications proved to be useful.In this paper; PubMed, the US national library of medicine, was utilized to review the literature in the last twenty years. Medline was reviewed for recent clinical trials, meta-analyses and review papers which have studied this important subject. Using the obtained information, current uses of breast MRI are discussed to determine the indications which are relevant to clinical practice.Worldwide; MRI is increasingly performed in different the commonest clinical scenarios for breast MRI will be reviewed in the next section to identify indications with the potential to improve patient care making them most applicable to clinical practice.for breast cancer is ranging from 85% to 100% (Heywang- AbstractAlthough mammography is the primary imaging modality for the breast, it has its limitations especially with dense breast parenchyma. Breast magnetic resonance imaging (MRI) has evolved into an important adjunctive tool as it is currently the most sensitive technique for breast cancer detection. Despite this high sensitivity, overlap in the appearances of some benign and malignant breast lesions results in additional unnecessary intervention with negative results. These false positives, in addition to high cost and limited availability, necessitate establishing proper indications for breast MRI. The literature was here reviewed for recent clinical trials, meta-analyses and review papers which have studied this important subject. PubMed; the US national library of medicine, was utilized to review the literature in the last twenty years. Using the obtained information, current uses of breast MRI are discussed in this paper to determine the indications which are relevant to clinical practice.

show abstract

“…Magnetic resonance imaging (MRI) is one of the most accurate imaging tools used to monitor and predict treatment response for patients undergoing chemotherapy (5–14). However, the predictive performance varies between different quantitative measurements derived from MRI, and by variations in the parameters that define those measurements.…”

Section: Introductionmentioning

confidence: 99%

Effect of MR Imaging Contrast Thresholds on Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer Subtypes: A Subgroup Analysis of the ACRIN 6657/I-SPY 1 TRIAL

Arasu

Newitt

et al. 2016

Tomography

View full text Add to dashboard Cite

Functional tumor volume (FTV) measurements by dynamic contrast-enhanced magnetic resonance imaging can predict treatment outcomes for women receiving neoadjuvant chemotherapy for breast cancer. Here, we explore whether the contrast thresholds used to define FTV could be adjusted by breast cancer subtype to improve predictive performance. Absolute FTV and percent change in FTV (ΔFTV) at sequential time-points during treatment were calculated and investigated as predictors of pathologic complete response at surgery. Early percent enhancement threshold (PEt) and signal enhancement ratio threshold (SERt) were varied. The predictive performance of resulting FTV predictors was evaluated using the area under the receiver operating characteristic curve. A total number of 116 patients were studied both as a full cohort and in the following groups defined by hormone receptor (HR) and HER2 receptor subtype: 45 HR+/HER2−, 39 HER2+, and 30 triple negatives. High AUCs were found at different ranges of PEt and SERt levels in different subtypes. Findings from this study suggest that the predictive performance to treatment response by MRI varies by contrast thresholds, and that pathologic complete response prediction may be improved through subtype-specific contrast enhancement thresholds. A validation study is underway with a larger patient population.

show abstract

Response monitoring of breast cancer patientsreceiving neoadjuvant chemotherapy using breast MRI – a review of current knowledge

Abstract: Background: Breast MRI is the most accurate method for evaluating treatment response in breast cancer patients receiving neoadjuvant chemotherapy (NAC).

Cited by 25 publications

References 50 publications

Study of Tumour Cellularity in Locally Advanced Breast Carcinoma on Neo-Adjuvant Chemotherapy

Study of Tumour Cellularity in Locally Advanced Breast Carcinoma on Neo-Adjuvant Chemotherapy

Breast Magnetic Resonance Imaging Indications in Current Practice

Effect of MR Imaging Contrast Thresholds on Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer Subtypes: A Subgroup Analysis of the ACRIN 6657/I-SPY 1 TRIAL

Contact Info

Product

Resources

About